Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine

Clinical Cancer Research

Volumn 4, Issue 3, 1998, Pages 721-730

  Haas, Claudia ^a   Strauß, Gudrun ^a   Moldenhauer, Gerd ^a   Iorio, Ronald M ^b   Schirrmacher, Volker ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE ANTIBODY; HN PROTEIN; MONOCLONAL ANTIBODY CD3; PROTEIN ANTIBODY; TUMOR CELL VACCINE;

ARTICLE; CANCER CELL; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG SYNTHESIS; HELPER CELL; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNOMODULATION; LEUKEMIA CELL LINE; NEWCASTLE DISEASE PARAMYXOVIRUS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VACCINE PRODUCTION;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD3; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; COLONIC NEOPLASMS; GAMMA RAYS; HN PROTEIN; HUMANS; HYBRIDOMAS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; JURKAT CELLS; LYMPHOCYTE ACTIVATION; NEWCASTLE DISEASE VIRUS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0031954533     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Cassel, W. A., and Garret, R. E. Newcastle disease virus as an antineoplastic agent. Cancer (Phila.), 18: 863, 1965.
2. Csatary, L., Eckhardt, S., and Kukosza, I. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect. Prev., 17: 619-627, 1993.
3. Cassel, W. A., and Murray, D. R. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med. Oncol. Tumor Pharmacother., 9: 169-171, 1992.
4. Lorence, R. M., Reichard, K. W., and Katubig, B. B. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J. Natl. Cancer Inst., 86: 1228-1233, 1994.
5. Liebrich, W., Schlag, P., Manasterski, M., Lehner B., Stöhr, M., Möller, P., and Schirrmacher V. In vitro and clinical characterization of a Newcastle disease virus-modified autologous tumor cell vaccine for treatment of colorectal cancer patients. Eur. J. Cancer, 27: 703-710, 1991.
6. Heicappell R., Schirrmacher, V., von Hoegen, P., Ahlert, T., and Appelhans, B. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. Int. J. Cancer, 37: 569-577, 1986.
7. Schirrmacher, V., Ahlert T., Heicappell, R., Appelhans, B., and von Hoegen, P. Successful application of non-oncogenic viruses for anti-metastatic cancer immunotherapy. Cancer Rev., 5: 19-49, 1986.
8. Plaksin, D., Progador, A., Vadai, E., Feldman, M., Schirrmacher, V., and Eisenbach, L. Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int. J. Cancer, 59: 796-801, 1994.
9. Schirrmacher, V., and Heicappell, R. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity. Clin. Exp. Metastasis, 5: 147-156, 1987.
10. Ertel, C., Millar, N. S., Emmerson, P. T., Schirrmacher, V., and von Hoegen, P. Viral hemagglutinin augments peptide specific cytotoxic T-cell responses. Eur. J. Immunol., 23: 2592-2596, 1993.
11. Jurianz, K., Haas, C., Hubbe, M., Ertel, C., Brunner, G., Altevogt, P., Schirrmacher, V., and von Hoegen, P. Adhesive function of Newcastle disease virus hemagglutinin in tumor-host interaction. Int. J. Oncol., 7: 539-545, 1995.
12. Von Hoegen, P., Zawathky, R., and Schirrmacher, V. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of Interferon, α, β. Cell. Immunol., 126: 80-90, 1990.
13. Schirrmacher, V., Haas, C., Bonifer, R., and Ertel, C. Virus potentiation of tumor vaccine T cell stimulatory capacity requires cell surface binding but not infection. Clin. Cancer Res., 3: 1135-1148, 1997.
14. Von Hoegen, P., Weber, E., and Schirrmacher, V. Modification of tumor cells by a low dose of Newcastle disease virus; augmentation of the tumor-specific T cell response in the absence of an anti-viral response. Eur. J. Immunol., 18: 1159-1166, 1988.
15. Iorio, R. M., Nicholson, P. M., and Bratt, M. A. Genetic variation within neutralizing domain on the HN-glycoprotein of NDV. J. Gen. Virol., 67: 1393-1402, 1986.
16. Köhler, G., and Milstein, C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature (Lond.), 256: 495-498, 1979.
17. Falkenberg, F. W., Weichert, H., Krane, B., Bartels, I., Palme, M., Nagels, H-O., and Fiebig, H. In vitro production of monoclonal antibodies in high concentration in a new and easy to handle modular minifermenter. J. Immunol. Methods, 179: 13-29, 1995.
18. Russell, P. H., and Alexander, D. J. Antigenic variation of Newcastle disease virus strains detected by monoclonal antibodies. Arch. Virol., 75: 243-253, 1983.
19. Schwartz, R. H. A cell culture model for T-lymphocyte clonal anergy. Science (Washington DC), 248: 1349-1356, 1990.
20. June, C. H., Ledbetter, J. A., Linsley, P. S., and Thompson, C. B. Role of the CD28 receptor in T-cell activation. Immunol. Today, 11: 211-216, 1990.
21. Chen, L., Linsley, P. S., and Hellström, K. E. Costimulation of T-cells for tumor immunity. Immunol. Today, 14: 483-486, 1993.
22. June, C. H., Bluestone, J. A., Nadler, L. M., and Thompson, C. B. The B7 and CD28 receptor families. Immunol. Today, 15: 321-331, 1994.
23. Bluestone, J. A. New perspectives of CD28-B7-mediated T-cell costimulation. Immunity, 2: 555-559, 1995.
24. Jung, G., Ledbetter, J. A., and Müller-Eberhard, H. J. Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc. Natl. Acad. Sci. USA, 84: 4611-4615, 1987.
25. Möller, S. A., and Reisfeld, R. A. Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T-lymphocytes. Cancer Immunol. Immunother., 33: 210-216, 1991.
26. Fanger, M. W. Bispecific Antibodies. Austin, TX: R. G. Landes Company, 1995.
27. van Raavensway Claasen, H. H., Eggermont, A. M. M., Nooyen, Y. A., Warnaar, S. O., and Fleuren, G. J. lmmunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL3/CD3 and OC/TR. Gynecol. Oncol., 52: 199-206, 1994.
28. Renner, C., Jung, W., Sahin, U., Denfeld, R., Pohl, C., Trümper, L., Hartmann, F., Diehl, V., van Lier, R., and Pfreundschuh, M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science (Washington DC), 264: 833-835, 1994.
29. Kroesen, B. J., Helfrich, W., Bakker, A., Wubbena, A. S., Bakker, H., Kal, H. B., The, T. H., and de Leij, L. Reduction of EGP-2-positive pulmonary metastases by bispecific-antibody-redirected T-cells in an immunocompetent rat model. Int. J. Cancer, 61: 812-818, 1995.
30. Nitta, T., Sato, K., Yagita, H., Okumura, K., and Ishii, S. Preliminary trial targeting therapy against malignant glioma. Lancet, 335: 368-371, 1990.
31. Bolhuis, R. L. H., Lamers, C. H. J., Goey, S. H., Eggermont, A. M. M., Trimbos, J. B. M. Z., Stoter, G., Lanzavecchia, A., Di Re, E., Miotti, S., Raspagliesi, F., Rivoltini, L., and Colnaghi, M. I. Adoptive immunotherapy of ovarian carcinoma with BS. mAb-targeted lymphocytes: a multicenter study. Int. J. Cancer, 7 (Suppl.): 78-81, 1992.
32. de Gast, G. C., Haagen, I. A., van Houten, A. A., Klein, S. C., Duits, A. J., de Weger, R. A., Vroom, T. M., Clark, M. R., Phillips, J., van Dijk, A. J. G., de Lau, W. B. M., and Bast, B. J. E. G. CD8 T cell activation after intravenous administration of CD3 × CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol. Immunother., 40: 390-396, 1995.
33. Canevari, S., Stoter, G., Arienti, F., Bolis, G., Colnaghi, M. I., Di Re, E. M., Eggermont, A. M. M., Goey, S. H., Gratama, J. W., Lamers, C. H. J., Nooy, M. A., Parmiani, G., Raspagliesi, F., Ravagnani, F., Scarfone, G., Trimbos, J. B., Wamaar, S. O., and Bolhuis, R. L. H. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst., 87: 1463-1469, 1995.
34. Jung, G., Honsik, C. J., Reisfeld, R. A., and Müller-Eberhard, H. J. Activation of human PBLs by anti-CD3: killing of tumor target cells coated with anti-target-anti-CD3-conjugates. Proc. Natl. Acad. Sci. USA, 83: 4479-4483, 1986.
35. van Dijk, J., Warnaar, S. O., van Eendenburg, J. D. H., Thienpont, M., Brakman, E., Boot, J. H. A., Fleuren, G. J., and Bolhuis, R. L. H. Induction of tumor-cell lysis by bispecific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen. Int. J. Cancer, 43: 344-349, 1989.
36. Haagen, I. A., Geerars, A. J., de Lau, W. B., Clark, M. R., van de Griend, R. J., Bast, B. J., and de Gast, B. C. Killing of autologous B-lineage malignancy using CD3 × CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood, 84: 556-563, 1994.
37. Ball, E. D., Guyre, P. M., Mills, L., Fisher, J., Dinces, N. B., and Fanger, M. W. Initial trial of bispecific antibody-mediated immunotherapy of CD15 bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 and anti-CD64. J. Hematother., 1: 89-95, 1992.
38. Wallace, P. K., Howell, A. L., and Fanger, M. W. Role of Fc γ receptors in cancer and infectious disease. J. Leukocyte Biol., 55: 816-826, 1994.
39. Hombach, A., Jung, W., Pohl, C., Renner, C., Sahin, U., Schmits, R., Wolf, J., Kapp, U., Diehl, V., and Pfreundschuh, M. A CDI6/CD30 bispecific antibody induces lysis of Hodgkin cells by unstimulated natural killer cells in vitro and in vivo. Int. J. Cancer, 55: 830-837, 1993.
40. 2. J. Natl. Cancer Inst., 85: 1003-1004, 1993.
41. Renner, C., Bauer, S., Sahin, U., Jung, W., van Lier, R., Jacobs, G., Held, G., and Pfreundschuh, M. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model. Blood, 87: 2930-2937, 1996.
42. Schlag, P., Manasterski, M., Gerneth, T., Hohenberger, P., Dueck, M., Herfarth, C., Liebrich, W., and Schirrmacher, V. Active specific immunotherapy with NDV modified autologous tumor cells following liver metastases resection in colorectal cancer: first evaluation of clinical response of a Phase II trial. Cancer Immunol. Immunother., 35: 325-330, 1992.
43. Ockert, D., Schirrmacher, V., Beck, N., Stoelben, E., Ahlert, T., Flechtenmacher, J., Hagmüller, E., Nagel, M., and Saeger, H. D. Newcastle disease virus infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin. Cancer Res., 2: 21-28, 1996.
44. Pomer, S., Schirrmacher, V., Thile, R., Löhrke, H., and Staehler, G. Tumor response and 4-year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous r-IL-2 and IFN-α2b. Int. J. Oncol., 6: 947-954, 1995.
45. Ahlert, T., Sauerbrei, W., Bastert, G., Ruhland, S., Bartik, B., Simiantonaki, N., Schumacher, J., Häcker, B., Schumacher, M., and Schirrmacher, V. Tumor cell number and viability as quality and efficacy parameters of autologous virus modified cancer vaccines. J. Clin. Oncol., 15: 1354-1366, 1997.
46. Liu, Y., and Janeway, C., Jr. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc. Natl. Acad. Sci. USA, 89: 3845-3849, 1992.
47. Cayeux, S., Beck, C., Aicher, A., Dörker, B., and Blankenstein, T. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur. J. Immunol., 25: 2325-2331, 1995.
48. Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., and Bluestone, J. H. CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1: 405, 1994.
49. Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
50. Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., Mc Gowan, P., and Linsley, P. S. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71: 1093-1102, 1992.
51. + T cells by B7-transfected melanoma cells. Science (Washington DC), 259: 368-370, 1993.
52. Schirrmacher, V., and von Hoegen, P. Importance of tumor cell membrane integrity and viability for CTL activation by cancer vaccines. Vaccine Res., 2: 183-196, 1993.
53. Toes, R. E. M., Offringa, R., Blom, R. J. J., Melief, C. J. M., and Kast, W. M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA. 93: 7855-7860, 1996.
54. Flens, M. J., Mulder, W. M. C., Bril, H., von Blomberg van de Flier, M. B., Scheper, R. J., and van Lier, R. A. Efficient expansion of tumor-infiltrating lymphocytes from solid tumors by stimulation with combined CD3 and CD28 monoclonal antibodies. Cancer Immunol. Immunother., 37: 323-328, 1993.
55. Linsley, P. S., and Ledbetter, J. A. The role of the CD28 receptor during T-cell responses to antigen. Annu. Rev. Immunol., 11: 191-212, 1993.